Merck Reports Data from the P-III (KEYLYNK-006) Study of Keytruda for Treatment of Metastatic Non-squamous NSCLC
Shots:
- The P-III (KEYLYNK-006) study investigates Keytruda + CT (pemetrexed + carboplatin/cisplatin) followed by either Keytruda + maintenance Lynparza or Keytruda + maintenance CT (pemetrexed) as a 1L treatment of metastatic non-squamous NSCLC without EGFR, ALK or ROS1 genomic tumor aberrations
- The study did not meet the dual 1EP of OS & PFS with Keytruda + CT followed by Keytruda + maintenance Lynparza. Full clinical evaluation is underway & will be shared with the scientific community
- The safety profiles of Keytruda and Lynparza were consistent with their prior individual studies
Ref: Merck | Image: Merck
Related News:- Merck Reports Results from the P-III (KEYNOTE-A18) Study of Keytruda for the Treatment of Cervical Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
